Shire submits Replagal for Fabry's disease in the US
This article was originally published in Scrip
Executive Summary
Shire has filed a BLA for its enzyme replacement therapy Replagal (agalsidase alfa) for Fabry's disease in the US. The product has been approved in the EU since 2001 for this indication, and is approved in 45 other countries.